Regulatory News:
Cellectis (Paris:ALCLS), the French genome engineering specialist, is today announcing that it has signed an agreement with Total to develop microalgae-based oil substitutes. The research program includes an initial one-year phase, which may be followed by a second phase lasting two to three years.
Over the long term, the use of microalgae could help supplement the offering for the chemical and energy markets, while reducing their environmental impacts.
The program's first phase will look into developing genome engineering methods and tools on certain microalgae species selected for their specific characteristics. The second phase would focus on trait engineering (specific changes to the metabolism and species) with a view to producing compounds which are currently derived from oil.
The application of Cellectis' genome engineering expertise, will accelerate the domestication and engineering of the microalgae species selected, paving the way for the production of oil product substitutes. Total will bring its experience in biotechnology R&D partnerships, as well as its know-how for the industrial-scale development of techniques and technology integration, combined with its knowledge of the oil and chemical sectors.
The costs for this joint program will be split equally between the two partners, as will ownership of the technologies and products created through this work by Cellectis and Total.
"This partnership with Total is going to help us develop our technology's potential in the field for oil product supplements", confirms André Choulika, Chairman and CEO of Cellectis. "This alliance involves major stakes since it is focused on developing products derived from renewable biological resources for the energy and chemical markets".
About Cellectis
Cellectis improves life by applying its
genome engineering expertise to a broad range of applications, including
human therapeutics, biological research and agriculture. Cellectis is
listed on the NYSE-Euronext Paris Alternext market (code: ALCLS).
To
find out more, visit www.cellectis.com.
Disclaimer
This press release and the information contained
herein do not constitute an offer to sell or subscribe, or a
solicitation of an offer tk buy or subscribe, for shares in Cellectis in
any country. This press release contains forward-looking statements that
relate to the Company's objectives based on the current expectations and
assumptions of the Company's management only and involve risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.
Contacts:
Cellectis
Marc Le Bozec
Chief Financial Officer
investisseurs@cellectis.com
or
Philippe
Valachs
Company Secretary
Tel: +33 (0)1 81 69 16 00
media@cellectis.com
or
Calyptus
Alexis
Breton / Cyril Combe
Tel: +33 (0)1 53 65 68 68
cellectis@calyptus.net
